Page last updated: 2024-09-02

ecteinascidin 743 and dacarbazine

ecteinascidin 743 has been researched along with dacarbazine in 16 studies

Compound Research Comparison

Studies
(ecteinascidin 743)
Trials
(ecteinascidin 743)
Recent Studies (post-2010)
(ecteinascidin 743)
Studies
(dacarbazine)
Trials
(dacarbazine)
Recent Studies (post-2010) (dacarbazine)
6601024047,5561,4633,429

Protein Interaction Comparison

ProteinTaxonomyecteinascidin 743 (IC50)dacarbazine (IC50)
Matrix metalloproteinase-9Homo sapiens (human)0.556

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's11 (68.75)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Biron, P; Blay, JY; Ray-Coquard, I1
Patel, SR1
Bui-Nguyen, B; Italiano, A; Toulmonde, M1
Bernasconi, S; Caccuri, AM; Capozzi, O; Chiorino, G; Clivio, L; D'Incalci, M; Damia, G; Di Giandomenico, S; Erba, E; Fossati, A; Fuso Nerini, I; Ganzinelli, M; Grosso, F; Mantovani, R; Marangon, E; Marchini, S; Margison, GP; Pastore, A; Rocchi, M; Romano, M; Sala, F; Tercero, JC; Uboldi, S; Watson, AJ1
Manson, SC; Penel, N; Powell, S; Sharma, S; Takyar, S1
Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M1
Dean, A; Demetri, GD; Elias, A; Ganjoo, K; Hensley, ML; Jones, RL; Khokhar, NZ; Knoblauch, RE; Maki, RG; Milhem, M; Parekh, TV; Park, YC; Patel, SR; Schuetze, SM; Spira, A; Staddon, A; Tawbi, H; Van Tine, BA; von Mehren, M1
Cousin, S; Penel, N; Peugniez, C1
Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V1
Demetri, GD; Elias, A; Hamm, J; Hensley, ML; Jones, RL; Knoblauch, R; Maki, RG; McCarthy, S; Milhem, M; Parekh, T; Patel, S; Schuetze, SM; Van Tine, BA; von Mehren, M; Wang, G1
Charlson, J; Chawla, SP; D'Amato, G; Demetri, GD; Forscher, C; Hensley, ML; Kaiser, P; Knoblauch, R; Livingston, M; Maki, RG; McCarthy, S; Parekh, T; Patel, S; Reed, DR; Rushing, D; Ryan, CW; Seth, R; Singh, A; von Mehren, M; Wang, G1
Chin, AL; Deresinski, S; Gong, CL; Srinivas, S; Studdert, AL1
Corbellari, R; De Luca, R; Nadal, L; Neri, D; Villa, A1
Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M1

Reviews

4 review(s) available for ecteinascidin 743 and dacarbazine

ArticleYear
[High-dose chemotherapy in soft tissue sarcomas of adults].
    Bulletin du cancer, 2001, Volume: 88, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Dioxoles; Dose-Response Relationship, Drug; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Isoquinolines; Sarcoma; Tetrahydroisoquinolines; Trabectedin

2001
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
    Expert opinion on investigational drugs, 2002, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin

2002
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin

2010
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
    BMC cancer, 2013, Aug-13, Volume: 13

    Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Failure

2013

Trials

3 trial(s) available for ecteinascidin 743 and dacarbazine

ArticleYear
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-10, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult

2016
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 09-01, Volume: 29, Issue:9

    Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Progression-Free Survival; Time Factors; Trabectedin; Young Adult

2018
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Cancer, 2019, 08-01, Volume: 125, Issue:15

    Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Survival Analysis; Trabectedin

2019

Other Studies

9 other study(ies) available for ecteinascidin 743 and dacarbazine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Dacarbazine; Dioxoles; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibronectins; Humans; Liposarcoma, Myxoid; Oncogene Proteins, Fusion; Promoter Regions, Genetic; RNA-Binding Protein FUS; Serum Amyloid P-Component; Signal Transduction; Temozolomide; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP; Tumor Suppressor Proteins; Ultraviolet Rays

2012
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl

    Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms

2015
Trabectedin is an effective second-line treatment in soft tissue sarcoma patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:3

    Topics: Dacarbazine; Dioxoles; Disease-Free Survival; Humans; Sarcoma; Tetrahydroisoquinolines; Trabectedin

2016
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 76

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays

2017
Application of pharmacoeconomics to formulary management in a health system setting.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Feb-21, Volume: 76, Issue:6

    Topics: Academic Medical Centers; Clinical Trials as Topic; Cost-Benefit Analysis; Dacarbazine; Drug Approval; Drug Costs; Drug Utilization Review; Economics, Pharmaceutical; Formularies as Topic; Humans; Interdisciplinary Communication; Markov Chains; Models, Economic; Neoplasms; Pharmaceutical Services; Pharmacy and Therapeutics Committee; Trabectedin; Treatment Outcome; United States; United States Food and Drug Administration

2019
The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors.
    Anti-cancer drugs, 2020, Volume: 31, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dacarbazine; Female; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred BALB C; Recombinant Fusion Proteins; Sarcoma; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
    Cancer medicine, 2021, Volume: 10, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascular Diseases; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Doxorubicin; Female; Heart; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Product Surveillance, Postmarketing; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Stroke Volume; Trabectedin; Ventricular Function, Left; Young Adult

2021